Navigation Links
Broad Spectrum Antibiotic Available for Antibiotic Resistant Bacteria

Tygacil (tigecycline)is a new, expanded broad-spectrum IV antibiotic that can be used for the treatment of a wide range of infections including those caused by antibiotic// resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). It will be available in the UK from today. Availability of this new antibiotic comes at a time when the need for effective new treatments is greater than ever and clinicians are running out of options.

"Difficult to treat, antibiotic-resistant and often life-threatening infections are a growing problem in the UK, costing the NHS an estimated additional £1 billion annually," says Dr Robert Masterton, Executive Medical Director and Consultant Microbiologist, NHS Ayrshire & Arran, "Even more worrying has been the emergence of the organisms commonly called 'superbugs' – those very worrying bacteria that have become resistant to a large number and in some cases all available antibiotics. Add to this the diminishing development of new antibiotics in the last 20 years and we could soon see a return to the Florence Nightingale era where infections caused more death than bullets because there were no effective drugs to treat these diseases. The introduction of tigecycline in the UK comes at absolutely the right time and will provide a vital new weapon in the fight against infection."

Tigecycline has been licensed for use in the UK as a treatment for a variety of complicated skin and soft tissue infections including infected wounds and complicated intra- abdominal infections such as complicated appendicitis.1 It is the world's first glycylcycline and has been developed by Wyeth to overcome two common mechanisms of resistance that have reduced the efficacy and limited the use of certain existing antibiotics.

While MRSA has received wide media and government attention and concern in the UK, other infections like Escherichia Coli (E. Coli) and Klebsiella could pose an even greater risk to public
'"/>




Page: 1 2

Related medicine news :

1. Tigecycline – New Generation Tetracycline With Broad Spectrum Antibacterial Activit
2. Plan To Connect Remote Aboriginal Communities Through Broadband
3. Low Doses Of Arsenic Have Broad Impact On Hormone Activity – Says A Researc
4. FDA Announces Audio Broadcasts on Emerging Drug Safety Information
5. Tigecycline – New Generation Tetracycline With Broad Spectrum Antibacterial Activit
6. Simple Eye Movement Test For Early Detection Of Fetal Alcohol Spectrum Disorder
7. Lack Of Social Skills Linked To Autism Spectrum Disorder (ASD)
8. Fetal Alcohol Spectrum Disorder in Children Can Be Diagnosed With Eye Movement Tests
9. Younger Siblings of Children With Autism Spectrum Disorders Score Low
10. Antibiotics Dangerous for Diarrhoea in Children Caused by E.Coli
11. Antibiotics Helps Autism
Post Your Comments:
(Date:7/22/2014)... Plate Club you eat pretty much everything you put ... Cornell University study shows that the average adult eats 92% ... plate. "If you put it on your plate, ... of the forthcoming book, Slim by Design, Professor of Marketing ... Wansink and co-author Katherine Abowd Johnson analyzed 1179 diners and ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 As reported on ... a caller request to name her favorite beauty products, “ ... on to say that “ Botox has changed my ... the makeup chair preparing for her various, daily appearances. ... explained Ms. Ripa (see: goo.gl/shmTQM). , “I think that Kelly ...
(Date:7/22/2014)... The Beryl Institute announces its fifth ... Scholar Program. These offerings reinforce the Institute’s commitment to ... healthcare and the need for rigorous research to understand ... scholar programs are intended to encourage and support ... focusing on the patient experience before, during and after ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 The market ... the past few years, owing to novel medical indications ... BoNTs in the aging societies where physical appearance is ... by one player, current competitors, new companies and technologies ... As biosimilar BoNTs will put the price of 1st-gen ...
(Date:7/22/2014)... NJ (PRWEB) July 22, 2014 CarePoint Health ... recently elected as the President of the medical staff at ... Levine will serve as President, as voted on by the ... of the medical staff in relation to the administration at ... needs of physicians and to work to make the Medical ...
Breaking Medicine News(10 mins):Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4Health News:Dr. Howard Levine Elected President of the Medical Staff at Bayonne Medical Center 2
... Deficiency Foundation LAS VEGAS and TOWSON, Md., May 5 ... that threatened their lives, Terri Cerda and her two ... Combined Immune Deficiency Disease (CIDD), will be featured on ... Edition." CIDD is one of the most severe types ...
... May 5 Baxter Regional Medical Center has recently ... patient satisfaction , in the National Database after ... They have also reached number one in Arkansas, number ... Compirion Healthcare Solutions, a hospital process improvement firm from ...
... May 5 The Cosmetic Bootcamp LLC, the leading ... meeting has reached capacity for sponsorship. According to Kenneth ... our expectations, even in this economy." He credits ... meeting as well as the boutique atmosphere that fosters ...
... May 5 Medifast, Inc. (NYSE: MED ) ... Control Center in Austin, Tx. The new Medifast Weight Control ... Louis Henna Dr., Suite 120 A, Round Rock, Tx 87664. ... log onto http://www.medifastcenters.com or ...
... discovered gene known as DEAR1 is mutated in breast cancer ... early-onset breast cancer, a research team headed by scientists at ... in the journal PLoS Medicine . , "The ... women have recurrences in the breast, and cancers that do ...
... study by the division of global child health ... cautions adoptive parents not to rely solely on ... immunizations. In the study, "Predictive Value of Immunization ... Internationally Adopted Children," division chief, Anna Maria Mandalakas, ...
Cached Medicine News:Health News:ABC's 'Extreme Makeover: Home Edition' Helps Family Coping with Primary Immunodeficiency Disease 2Health News:ABC's 'Extreme Makeover: Home Edition' Helps Family Coping with Primary Immunodeficiency Disease 3Health News:Compirion Helps Baxter Regional Medical Center Achieve Patient Satisfaction Rankings in the Top 5th Percentile Nationally 2Health News:Compirion Helps Baxter Regional Medical Center Achieve Patient Satisfaction Rankings in the Top 5th Percentile Nationally 3Health News:Compirion Helps Baxter Regional Medical Center Achieve Patient Satisfaction Rankings in the Top 5th Percentile Nationally 4Health News:Compirion Helps Baxter Regional Medical Center Achieve Patient Satisfaction Rankings in the Top 5th Percentile Nationally 5Health News:Compirion Helps Baxter Regional Medical Center Achieve Patient Satisfaction Rankings in the Top 5th Percentile Nationally 6Health News:Medifast Weight Control Center Opens in Round Rock, TX 2Health News:Novel gene predicts local recurrence in early-onset breast cancer 2Health News:Novel gene predicts local recurrence in early-onset breast cancer 3Health News:Parents of internationally adopted children advised to verify children's immunization levels 2
(Date:7/22/2014)... , July 22, 2014  NeuroSigma, Inc. (NeuroSigma), ... focused on commercialization of its non-invasive Monarch ... and neuropsychiatric disorders, today announced that enrollment has begun ... nerve stimulation (eTNS) as adjunctive therapy for the treatment ... being conducted at the Olive View-UCLA Medical Center in ...
(Date:7/22/2014)... York , July 22, 2014 ... Partnerschaft für umfassenden Schutz von Pharmazeuten ... Österreich    Equashield ( ... Transfersystemen (Closed System Transfer Devices, CSTDs) für gefährliche ... einen Vertriebshändler und Hersteller von medizinischen ...
(Date:7/21/2014)... McCord Research, Inc. was recently granted ... This patent describes a method for accelerating wound ... inventor, Dr. McCord, this method includes administering or ... composition of an effective amount of hydroxytyrosol and ... such that the administration of the combination reduces ...
Breaking Medicine Technology:Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2US Patent Office Grants McCord Research Endothelial Cell Treatment Patent 2
... well-tolerated with signs of durable,disease control in advanced ... /PRNewswire-FirstCall/ -- IDM,Pharma, Inc. today presented preliminary results ... trial (DC-MEL-202). The,results showed that UVIDEM was well ... response in patients with,progressive metastatic melanoma. , The ...
... trial presented at ENDO 2007 , ,- Regulatory approvals ... recruitment in Europe , ,MONTREAL, QUEBEC -- (MARKET WIRE) ... that 26-week data from,its first Phase 3 study testing ... ENDO, the 89th,annual meeting of the Endocrine Society. The ...
Cached Medicine Technology:IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 2IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 3IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 4IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 5Theratechnologies: TH9507 Phase 3 Clinical Update 2Theratechnologies: TH9507 Phase 3 Clinical Update 3
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
... The innovative E.coli ... Pro-Lab offers definitive identification ... the use of a ... the possibility of cross-reactions ...
... Directigen™ Meningitis Individual Tests are ... for the direct qualitative detection ... type b, S. pneumoniae, N. ... coli K1 in cerebrospinal fluid ...
Inquire...
Medicine Products: